R. Langley

Publications233
h-index58
Citations15,951
Highly Influential Citations473
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • K. Reich
  • 602 Publications • 26,808 Citations
  • K. Papp
  • 502 Publications • 28,838 Citations
  • A. Gottlieb
  • 743 Publications • 36,029 Citations
  • M. Lebwohl
  • 1,039 Publications • 41,194 Citations
  • Publications
  • Influence
Secukinumab in plaque psoriasis--results of two phase 3 trials.
TLDR
Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
View on PubMed
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
View on PubMed
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
TLDR
Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
View on PubMed
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
View on PubMed
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
View on PubMed
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
View on Elsevier
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
TLDR
Briakinumab showed higher efficacy than methotrexate in patients with moderate-to-severe psoriasis, and serious infections and cancers occurred more frequently with briakinumabs, but the differences were not significant.
View PDF
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
View on Elsevier
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
View on PubMed
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
TLDR
Extended exposure to 50 mg of etanercept twice weekly resulted in exposure-adjusted rates of adverse events and infections similar to those in patients receiving placebo, and improvements in physician- and patient-reported measures of psoriasis severity were observed for up to 96 weeks of continuous etanerscept therapy.
View on PubMed
...
...